Johnson & Johnson

U.S. FDA Approves TREMFYA® (Guselkumab) for Pediatric Plaque Psoriasis and Active Psoriatic Arthritis — First IL-23 Inhibitor Cleared for Children

U.S. FDA Approves TREMFYA® (Guselkumab) for Pediatric Plaque Psoriasis and Active Psoriatic Arthritis — First IL-23 Inhibitor Cleared for Children

29 Sep 2025

2 min read

Dr. Reddy’s Laboratories Ltd. Acquires Stugeron Brand from Johnson & Johnson for $50.5 Million

11 Sep 2025

1 min read

Johnson & Johnson MedTech Launches KINCISE™ 2 System to Enhance Orthopaedic Surgery Efficiency and Reduce Surgeon Fatigue

Medical Devices

Johnson & Johnson MedTech Launches KINCISE™ 2 System to Enhance Orthopaedic Surgery Efficiency and Reduce Surgeon Fatigue

04 Jun 2025

2 min read

Read More

Voice Of HealthCare

vohnetwork.com